Weekly Roundup: With great power comes a place on the Medicine Maker Power List. Optimum’s clients have the power.

/in

ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]

Read more

Weekly Roundup: Keeping score on the sector

/in

Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline Cambridge (UK) based Mission Therapeutics, a clinical-stage biotechnology company developing novel therapeutics that promote the removal of dysfunctional mitochondria to restore cellular health and function, announced the divestment of MTX652, […]

Read more

Hot Topic: Where do you get your news?

/in

SOMETHING momentous happened in the world of media earlier this month.Social media and video platforms overtook “traditional” news organisations as the most popular source of news. The results are from a highly-respected global annual survey about how news is sourced and consumed, by the Reuters Institute and Oxford University. I actually first heard about this […]

Read more

Weekly Roundup: Transformative tech at ON Helix 2026

/in

Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]

Read more

Weekly Roundup: The latest in first-in-class biotech and medtech

/in

Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]

Read more
© Optimum Strategic Communications.